Workshops
Will Europe’s Pharmaceutical Policy and HTA Stakeholders Respond to Medicare Price Negotiation?
Moderator: Sean D. Sullivan
Monday, November 18. 10:15 – 11:15
Balancing Budgets and Breakthroughs: Does Budget Impact Analysis Systematically Disadvantage Gene Therapies?
Panelist: Scott Ramsey
13:45 – 14:45
Poster Presentations
Modeling Challenges for Cancer Drugs With Unprecedented Outcomes: Lorlatinib in the First Line Setting of ALK+ aNSCLS As a Case Study
Williams TL, Le H, Doan J, Zala D, Rifi N, Bloudek L, Ramsey S
Economic Evaluation of Dupilumab Versus Best Supportive Care for the Treatment of Adult Patients With Moderate-to-Severe Prurigo Nodularis in the United States
Tavi J, Bahloul D, Kuznik A, Thomas RB, Knight C, Manga N, Levin L-A, Sullivan SD
Baseline Risk of Hospitalization and Death in a Nirmatrelvir/Ritonavir Treatment-Eligible Population With Mild-to-Moderate COVID-19 in the United States: A Systematic Literature Review
Migliaccio-Walle K, Mugwagwa T, Cha-Silva A, Gong CL, Campbell D, Nguyen JL, Quercia R, Bergroth T, Veenstra D, Moran MM, Dzingina M
Influence of Initial Imaging Type on Time-to-Diagnosis Among Cancers Without Routine Screening Programs: A SEER-Medicare Study
Xiting Cao X, Chen Y, Brouwer E, Ramsey S, Tyson C, Rego S, Choudhry O, Veenstra D, Ebbert J, Beer T